Every 8-K that MINIMED GROUP INC (MMED) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MMED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MMED filings page.
MiniMed Group, Inc. (MMED) reported strong first-quarter fiscal 2027 results for the period ended July 31, 2026, with worldwide net sales of $843 million, up 16.6% as reported and 15.8% on an organic basis. U.S. net sales were $240 million, up 13.1%, while international net sales were $603 million, up 18.1% as reported and 16.9% organic. Results included an estimated 4%–6% benefit from an extra fiscal week, with underlying low double-digit organic growth.
By product, pump revenue rose to $144 million (+21.5%), consumables to $261 million (+13.8%), and CGM to $431 million (+19.9%). Operating income improved to $5 million from a $13 million loss, and net income attributable to the company was approximately breakeven versus a $19 million loss a year earlier. Worldwide new pumps sold were about 34,000, up 7.7%, and the CGM attachment rate reached 69%, up roughly 100 bps sequentially.
MiniMed highlighted rapid adoption of MiniMed Flex™ in the U.S. and significant pipeline progress, including FDA submission of the MiniMed Fit™ patch pump, CE Mark for MiniMed Flex™, completion of enrollment in the U.S. pivotal trial for the Vivera™ fully-closed loop algorithm, and IDE approval for a next-generation extended-wear sensor. For fiscal 2027, MiniMed raised its organic revenue growth outlook to approximately 10.5% (including a 1.0%–1.5% extra-week benefit) from about 10% and reaffirmed its target adjusted EBITDA margin of roughly 16%.
MiniMed Group, Inc. disclosed that Courtney Nelson Wills, Senior Vice President, General Counsel and Corporate Secretary, has decided to resign from her position. She notified the company on July 30, 2026, and her resignation will be effective September 25, 2026 following an 8‑week transition period.
The company states that Ms. Nelson Wills is leaving for personal reasons, having accepted a role outside the medical device industry, and that her departure is not due to any disagreement with MiniMed. MiniMed is conducting a search for a successor and emphasizes its commitment to maintaining strong legal, governance, and compliance oversight during the transition. The disclosure also includes standard forward‑looking statements language referencing risks and uncertainties described in its SEC reports.
MiniMed Group, Inc. announced governance updates and its next shareholder meeting plans. The Board of Directors increased its size from nine to 11 members and appointed David Endicott and Linnea Burman as new directors, effective June 29, 2026.
Endicott will serve as a Class I director with a term expiring at the 2026 annual meeting and join the Compensation and Talent Committee. He is currently Chief Executive Officer and a director of Alcon, Inc., and has prior senior roles at several healthcare companies. The Board determined he is independent under Nasdaq, SEC and company guidelines.
Burman, a senior executive at Medtronic plc, will serve as a Class II director with a term expiring at the 2027 annual meeting. While Medtronic remains an affiliate of MiniMed, she will not receive Board compensation. MiniMed also set its 2026 annual meeting of stockholders for October 9, 2026, with an August 11, 2026 record date and mid‑July deadlines for shareholder proposals and nominations.
MiniMed Group, Inc. reported strong fourth quarter and full fiscal year 2026 revenue growth but remained unprofitable. Fourth quarter net sales were $837 million, up 15.6% as reported and 8.7% organic, driven largely by international markets and continuous glucose monitoring (CGM) products. Full-year net sales reached $3.102 billion, up 14.2% as reported and 8.0% organic, marking the first time MiniMed surpassed $3 billion in annual revenue.
Despite this top-line strength, MiniMed posted a fiscal 2026 net loss attributable to the company of $331 million, widening from $213 million a year earlier, with a basic and diluted loss per share of $1.29. Fourth quarter net loss attributable to the company was $183 million. CGM revenue grew faster than pumps, and the worldwide CGM attachment rate rose to 66% for the year, with approximately 659,000 pump users at year-end.
Looking ahead to fiscal 2027, MiniMed targets organic revenue growth of about 10%, including a modest benefit from an extra week in the fiscal year, and an adjusted EBITDA margin of about 16%. The company highlighted multiple recent product launches and regulatory clearances as key drivers for future growth.
MiniMed Group, Inc. reported that director Brett Wall, a class II member of the Board and of the Nominating and Corporate Governance Committee, has notified the company he will resign from the Board effective July 3, 2026. The company states his decision is not due to any disagreement with management or the Board, but follows his departure from a senior leadership role at Medtronic plc, MiniMed’s parent, which originally nominated him.
To fill the vacancy, Scott Cundy was appointed as a director effective July 3, 2026. He will serve as a class II director with a term expiring at the 2027 annual meeting of stockholders and will join the Nominating and Corporate Governance Committee. Cundy is a senior Medtronic executive overseeing global quality, product development, and innovation. While Medtronic remains an affiliate of MiniMed, he will receive no compensation for Board service; if that changes, his pay will align with MiniMed’s non‑employee director program.
MiniMed Group, Inc. reported that its parent, Medtronic plc, experienced unauthorized access to certain information technology systems. Medtronic stated it promptly contained the incident, activated incident response protocols, and engaged external cybersecurity experts to investigate and remediate.
Medtronic disclosed it has not identified any impact on its products, patient safety, customer connections, manufacturing and distribution operations, financial reporting systems, or ability to meet patient needs, and does not expect a material impact on its business or financial results. MiniMed is not aware of compromises to its own IT systems and does not currently expect a material impact on its business or financial results.
The filing also outlines potential risks if the situation worsens, including possible data release or misuse, operational and financial impacts, management distraction, litigation, strained third-party relationships, reputational harm, and regulatory scrutiny, and includes standard forward-looking statement cautions.
MiniMed Group, Inc. adopted a new Severance Pay Plan for Executives and a Change of Control Severance Plan for its named executive officers. Executives at vice president level and above become eligible for severance after certain terminations if they sign a release of claims and meet plan conditions.
For eligible terminations not tied to a change of control, each named executive officer may receive a lump-sum cash payment equal to two times annual base salary plus target bonus, and a lump-sum equal to 24 months of medical and dental COBRA premiums. Equity awards generally do not continue vesting unless the executive is retirement-eligible.
Following a change of control, each named executive officer is promised three years of employment on terms no less favorable than those in place beforehand. If they are terminated without cause or resign for good reason during that period, they may receive a pro-rated annual bonus, a lump sum equal to three times base salary plus the highest recent annual bonus, three additional years of credited retirement benefits, and three years of continued health and life insurance benefits. The plan also includes a mechanism to adjust benefits if excise taxes under Section 4999 of the Internal Revenue Code would apply.
MiniMed Group, Inc. announced that the U.S. Food and Drug Administration has cleared the MiniMed Flex™, a next-generation, discreet, smartphone-controlled insulin pump. The clearance came several months earlier than anticipated and will allow earlier commercialization of this key product.
Development of MiniMed Flex™ was funded in part by affiliates of Blackstone Life Sciences Advisors L.L.C. Under their agreement, during the first two years following U.S. regulatory approval and commercial launch, Blackstone will receive the greater of a mid-to-high single digit royalty percentage on applicable net sales or a minimum payment of $157 million. MiniMed expects to recognize a one-time charge of $157 million in the fourth quarter of fiscal year 2026 related to these future payments.
MiniMed Group, Inc. completed its initial public offering of 28,000,000 shares of common stock at $20.00 per share, generating net proceeds of approximately $538 million. The company retained $309 million, resulting in approximately $350 million of cash on hand, and used the remainder to repay intercompany debt owed to Medtronic.
MiniMed was separated from Medtronic’s Diabetes business, with Medtronic now owning approximately 90.03% of outstanding shares. The company established a $500 million five-year senior secured revolving credit facility for working capital and general corporate purposes, reconstituted its board and committees, and adopted new equity, incentive, deferred compensation, and retirement plans for directors and executives.